Marathon Patent Group Announces USPTO Ruling Granting Joint Motion to Terminate Brainlab AG and Varian Medical Systems, Inc's Petition for Inter Partes Review of Sarif Biomedical Patent

LOS ANGELES, CA -- (Marketwired) -- 12/03/14 -- Marathon Patent Group, Inc. (NASDAQ: MARA) ("Marathon"), a patent licensing company, announced today that on December 1, 2014, the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office (USPTO) granted a joint motion to terminate IPR2014-00753.

The court ruled, "On November 4, 2014, we instituted an inter partes review of claims 10 and 11, but not remaining claims 1-9 of the '725 patent. Patent Owner has filed a statutory disclaimer under 35 U.S.C. § 253(a) and 37 C.F.R. § 1.321(a) disclaiming claims 10 and 11, all of the claims of the '725 patent on which a trial was instituted in the instant proceeding. Consequently, there are no patent claims remaining in this inter partes review. Under these circumstances, we determine that it is appropriate to enter judgment and terminate the trial without rendering a final written decision."

"We were pleased with the USPTO's initial decision in early November denying Brainlab AG and Varian Medical Systems, Inc.'s IPR petition on claims 1-9," said Doug Croxall, Founder and CEO of Marathon Patent Group. "As a result of the earlier decision, Sarif's infringement suits will be unaffected since none of Sarif's asserted claims were subject to invalidation via the instituted IPR."

Croxall continued, "Hopefully our voluntarily disclaiming of claims 10 and 11 of the 725 patent resulting in the termination of the proceeding, combined with the earlier IPR denial with respect to claims 1-9, will encourage the parties in suit to reach reasonable licensing arrangements with Sarif Biomedical."

About Marathon Patent Group:
Marathon is a patent acquisition and monetization company. The Company acquires patents from a wide-range of patent holders from individual inventors to Fortune 500 companies. Marathon's strategy of acquiring patents that cover a wide-range of subject matter allows the Company to achieve diversity within its patent asset portfolio. Marathon generates revenue with its diversified portfolio through actively managed concurrent patent rights enforcement campaigns. This approach is expected to result in a long-term, diversified revenue stream. To learn more about Marathon Patent Group, visit

Safe Harbor Statement
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the Securities and Exchange Commission (the "SEC"), not limited to Risk Factors relating to its patent business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.


Addo Communications
Lasse Glassen

Marathon Patent Group
Daniel Gelbtuch
Chief Marketing Officer

Source: Marathon Patent Group, Inc.